Identification of diagnostic DNA methylation markers in the blood of Japanese Alzheimer’s disease patients using methylation capture sequencing DOI
Risa Mitsumori,

Kazuhide Sawamura,

Kimi Yamakoshi

и другие.

Research Square (Research Square), Год журнала: 2025, Номер unknown

Опубликована: Апрель 3, 2025

Abstract Background Methylation capture sequencing (MC-seq), which relies on next-generation technology, offers advantages over the widely used array-based approach that Illumina Inc. developed regarding both resolution and comprehensiveness for detecting DNA methylation changes across genomes. In present study, MC-seq was employed first time to identify markers Alzheimer’s disease (AD). Results We compared in blood of 12 AD patients with brain amyloidosis cognitively normal elderly Japanese individuals without amyloidosis. Candidate differences were validated two cohorts using bisulfite amplicon sequencing. Significant differentially methylated regions identified ANKH, MARS, ANKFY1, LINC00908, KLF2 genes a slight change CHRNE (p = 0.061). Furthermore, our diagnostic prediction model showed combining levels ANKH MARS APOE genotype provided accuracy, achieving AUCs 0.90 0.81 discovery validation datasets, respectively. Conclusions The results suggest potential these diagnosing support validity identifying disease-related

Язык: Английский

Cortical Diffusivity, a Biomarker for Early Neuronal Damage, Is Associated with Amyloid-β Deposition: A Pilot Study DOI Creative Commons
Justine Debatisse,

Fangda Leng,

Azhaar Ashraf

и другие.

Cells, Год журнала: 2025, Номер 14(3), С. 155 - 155

Опубликована: Янв. 21, 2025

Pathological alterations in Alzheimer’s disease (AD) begin several years prior to symptom onset. Cortical mean diffusivity (cMD) may be used as a measure of early grey matter damage AD it reflects the breakdown microstructural barriers preceding volumetric changes and affecting cognitive function. We investigated cMD trajectory evaluated influence amyloid-β (Aβ) tau deposition. In this cross-sectional study, we analysed multimodal PET, DTI, MRI data 87 participants, stratified them into Aβ-negative -positive, cognitively normal, mildly impaired, patients. was significantly increased Aβ-positive MCI compared with CN frontal, parietal, temporal cortex, hippocampus, medial lobe. correlated cortical thickness only patients without Aβ deposition but not Our results suggest that is an marker neuronal since observed simultaneously subjects driven by tau, suggesting direct toxicity or associated inflammation causes neurons. provide information about before macrostructural changes.

Язык: Английский

Процитировано

0
Identification of diagnostic DNA methylation markers in the blood of Japanese Alzheimer’s disease patients using methylation capture sequencing DOI
Risa Mitsumori,

Kazuhide Sawamura,

Kimi Yamakoshi

и другие.

Research Square (Research Square), Год журнала: 2025, Номер unknown

Опубликована: Апрель 3, 2025

Abstract Background Methylation capture sequencing (MC-seq), which relies on next-generation technology, offers advantages over the widely used array-based approach that Illumina Inc. developed regarding both resolution and comprehensiveness for detecting DNA methylation changes across genomes. In present study, MC-seq was employed first time to identify markers Alzheimer’s disease (AD). Results We compared in blood of 12 AD patients with brain amyloidosis cognitively normal elderly Japanese individuals without amyloidosis. Candidate differences were validated two cohorts using bisulfite amplicon sequencing. Significant differentially methylated regions identified ANKH, MARS, ANKFY1, LINC00908, KLF2 genes a slight change CHRNE (p = 0.061). Furthermore, our diagnostic prediction model showed combining levels ANKH MARS APOE genotype provided accuracy, achieving AUCs 0.90 0.81 discovery validation datasets, respectively. Conclusions The results suggest potential these diagnosing support validity identifying disease-related

Язык: Английский

Процитировано

0